BIO-FD&C Co.,Ltd. (KOSDAQ:251120)
8,870.00
+50.00 (0.57%)
At close: Sep 3, 2026
BIO-FD&C Revenue
BIO-FD&C had revenue of 5.36B KRW in the quarter ending June 30, 2026, with 14.55% growth. This brings the company's revenue in the last twelve months to 19.53B, up 12.64% year-over-year. In the year 2025, BIO-FD&C had annual revenue of 19.18B with 19.37% growth.
Revenue (ttm)
19.53B
Revenue Growth
+12.64%
P/S Ratio
4.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
78.26B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.18B | 3.11B | 19.37% |
| Dec 31, 2024 | 16.07B | 474.34M | 3.04% |
| Dec 31, 2023 | 15.59B | -263.23M | -1.66% |
| Dec 31, 2022 | 15.86B | 3.88B | 32.43% |
| Dec 31, 2021 | 11.97B | 3.33B | 38.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| Psomagen | 60.70B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.79B |
| CORESTEMCHEMON | 18.29B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.51B |
| EyeGene | 4.02B |